Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Insight into cardiovascular risk factors in patients with acromegaly.

Literature DB >> 24415173

Insight into cardiovascular risk factors in patients with acromegaly.

Maria Fleseriu¹.

Abstract

Entities: Disease Species

Mesh：

Year: 2014 PMID： 24415173 DOI： 10.1007/s12020-013-0157-y

Source DB: PubMed Journal: Endocrine ISSN： 1355-008X Impact factor: 3.633

× No keyword cloud information.

10 in total

1. Left ventricular synchronicity in acromegaly.

Authors: Ludovica F S Grasso; Annamaria Colao
Journal: Endocrine Date: 2013-06-27 Impact factor: 3.633

Review 2. Diagnosis and treatment of acromegaly and its complications: consensus guidelines.

Authors: S Bonadonna; M Doga; M Gola; G Mazziotti; A Giustina
Journal: J Endocrinol Invest Date: 2005 Impact factor: 4.256

3. Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study.

Authors: Annamaria Colao; Rosario Pivonello; Ludovica Francesca Stella Grasso; Renata Simona Auriemma; Mariano Galdiero; Silvia Savastano; Gaetano Lombardi
Journal: Eur J Endocrinol Date: 2011-08-25 Impact factor: 6.664

4. GH levels and insulin sensitivity are differently associated with biomarkers of cardiovascular disease in active acromegaly.

Authors: L Boero; M Manavela; T Meroño; P Maidana; L Gómez Rosso; F Brites
Journal: Clin Endocrinol (Oxf) Date: 2012-10 Impact factor: 3.478

5. Cardiovascular events in acromegaly: distinct role of Agatston and Framingham score in the 5-year prediction.

Authors: Marta Ragonese; Angela Alibrandi; Gianluca Di Bella; Ignazio Salamone; Soraya Puglisi; Oana Ruxandra Cotta; Maria Luisa Torre; Francesco Ferrau; Rosaria Maddalena Ruggeri; Francesco Trimarchi; Salvatore Cannavo
Journal: Endocrine Date: 2013-11-27 Impact factor: 3.633

6. Oxidative stress and reduced antioxidative status, along with endothelial dysfunction in acromegaly.

Authors: P Anagnostis; Z A Efstathiadou; S Gougoura; S A Polyzos; E Karathanasi; P Dritsa; M Kita; G N Koukoulis
Journal: Horm Metab Res Date: 2012-10-23 Impact factor: 2.936

Review 7. Acromegaly pathogenesis and treatment.

Authors: Shlomo Melmed
Journal: J Clin Invest Date: 2009-11-02 Impact factor: 14.808

8. Cardiac risk in patients with treatment naïve, first-line medically controlled and first-line surgically cured acromegaly in comparison to matched data from the general population.

Authors: C Berg; S Petersenn; M Walensi; S Möhlenkamp; M Bauer; N Lehmann; U Roggenbuck; S Moebus; M Broecker-Preuss; I E Sandalcioglu; D Stolke; U Sure; K H Joeckel; R Erbel; D Führer; K Mann
Journal: Exp Clin Endocrinol Diabetes Date: 2013-01-21 Impact factor: 2.949

Review 9. Systemic complications of acromegaly: epidemiology, pathogenesis, and management.

Authors: Annamaria Colao; Diego Ferone; Paolo Marzullo; Gaetano Lombardi
Journal: Endocr Rev Date: 2004-02 Impact factor: 19.871

10. A consensus on the diagnosis and treatment of acromegaly complications.

Authors: S Melmed; F F Casanueva; A Klibanski; M D Bronstein; P Chanson; S W Lamberts; C J Strasburger; J A H Wass; A Giustina
Journal: Pituitary Date: 2013-09 Impact factor: 4.107

10 in total

5 in total

1. Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.

Authors: Claire Briet; Mirela Diana Ilie; Emmanuelle Kuhn; Luigi Maione; Sylvie Brailly-Tabard; Sylvie Salenave; Bertrand Cariou; Philippe Chanson
Journal: Endocrine Date: 2018-11-05 Impact factor: 3.633